Page last updated: 2024-08-16

quetiapine and clozapine

quetiapine has been researched along with clozapine in 24 studies

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (8.33)18.2507
2000's11 (45.83)29.6817
2010's10 (41.67)24.3611
2020's1 (4.17)2.80

Authors

AuthorsStudies
De Loore, K; Gommeren, W; Janssen, PF; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van Gompel, P1
Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L1
Bristow, LJ; Hutson, PH; Rowley, M1
Klitgaard, H; Matagne, A; Talaga, P1
Gatos, GC; Kirkland, KM; McLaren, FM; Migler, BM; Needles, AL; Nelson, CL; Ohnmacht, CJ; Warawa, EJ1
Boulton, DW; DeVane, CL; Liston, HL; Markowitz, JS1
Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S1
Wermuth, CG1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C1
Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT1
Ablordeppey, SY; Altundas, R; Bricker, B; Jackson, T; Khan, A; Kumar, EV; Roth, BL; Zhu, XY1
Ahman, M; Holmén, AG; Wan, H1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Sen, S; Sinha, N1
Bartolome, JM; Langlois, X; Macdonald, GJ; Tresadern, G1
Andres-Mach, M; Czuczwar, S; Dawidowski, M; Herold, F; Kleps, J; Mazurek, A; Mazurek, AP; Nowak, G; Pluciński, F; Stachowicz, K; Stefanowicz, J; Szewczyk, B; Sławińska, A; Słowiński, T; Wolska, I; Łuszczki, JJ1
Deville, M; Dilly, S; Lamy, C; Liégeois, JF; Mangin, F; Résimont, M; Tarazi, FI1
Dalvie, D; Loi, CM; Smith, DA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Andres-Mach, M; Bączek, T; Belka, M; Czuczwar, SJ; Gomółka, AE; Herold, F; Jastrzębska-Więsek, M; Nowak, G; Partyka, A; Siwek, A; Stefanowicz, J; Słowiński, T; Turło, J; Ulenberg, S; Wesołowska, A; Wróbel, MZ; Zagaja, M; Żołnierek, M; Łuszczki, JJ1
Azmanova, M; Barry, NPE; Pitto-Barry, A1
Freeman, BB; Rankovic, Z; Yang, L1
Horiguchi, M; Ishida, K; Isobe, Y; Nakako, T; Watanabe, H; Yamamoto, M1

Reviews

5 review(s) available for quetiapine and clozapine

ArticleYear
Current and novel approaches to the drug treatment of schizophrenia.
    Journal of medicinal chemistry, 2001, Feb-15, Volume: 44, Issue:4

    Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Mice; Mice, Transgenic; Nitric Oxide Synthase; Receptor, Serotonin, 5-HT2A; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Receptors, Serotonin; Schizophrenia; Serotonin Antagonists

2001
Selective optimization of side activities: another way for drug discovery.
    Journal of medicinal chemistry, 2004, Mar-11, Volume: 47, Issue:6

    Topics: Animals; Biological Availability; Combinatorial Chemistry Techniques; Databases, Factual; Drug Design; Humans; Patents as Topic; Pharmaceutical Preparations; Structure-Activity Relationship

2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Schizophrenia: synthetic strategies and recent advances in drug design.
    MedChemComm, 2018, May-01, Volume: 9, Issue:5

    Topics:

2018
Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
    European journal of medicinal chemistry, 2019, Nov-15, Volume: 182

    Topics: Animals; Blood-Brain Barrier; Central Nervous System; Central Nervous System Agents; Drug Delivery Systems; Drug Discovery; Humans; Molecular Structure; Structure-Activity Relationship

2019

Other Studies

19 other study(ies) available for quetiapine and clozapine

ArticleYear
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
    Psychopharmacology, 1996, Volume: 124, Issue:1-2

    Topics: Animals; Antipsychotic Agents; Brain; Cells, Cultured; Clozapine; Haloperidol; Humans; Male; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone

1996
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
    European journal of pharmacology, 1998, Aug-21, Volume: 355, Issue:2-3

    Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes

1998
Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
    Bioorganic & medicinal chemistry letters, 2001, May-21, Volume: 11, Issue:10

    Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Mice; Piperidines; Protein Binding; Psychomotor Agitation; Psychotic Disorders; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists

2001
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
    Journal of medicinal chemistry, 2001, Feb-01, Volume: 44, Issue:3

    Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Cebus; Dibenzothiazepines; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Male; Mice; Quetiapine Fumarate; Receptors, Dopamine D2; Stereoisomerism; Structure-Activity Relationship

2001
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.
    Life sciences, 2002, May-31, Volume: 71, Issue:2

    Topics: Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepines; Binding, Competitive; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Kinetics; Olanzapine; Pirenzepine; Quetiapine Fumarate; Recombinant Proteins; Risperidone

2002
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:3

    Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain

2003
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Feb-27, Volume: 104, Issue:9

    Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain

2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
    Journal of medicinal chemistry, 2007, Oct-18, Volume: 50, Issue:21

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain

2007
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
    Bioorganic & medicinal chemistry, 2008, Aug-01, Volume: 16, Issue:15

    Topics: Animals; Antipsychotic Agents; Apomorphine; Azepines; Butyrophenones; Clozapine; Haloperidol; Lethal Dose 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Structure-Activity Relationship

2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
    Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6

    Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry

2009
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011
Molecular properties affecting fast dissociation from the D2 receptor.
    Bioorganic & medicinal chemistry, 2011, Apr-01, Volume: 19, Issue:7

    Topics: Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Drug Design; Humans; Molecular Structure; Receptors, Dopamine D2; Structure-Activity Relationship

2011
Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:9

    Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Mice; Models, Molecular; Radioligand Assay; Rats; Receptors, Neurotransmitter; Structure-Activity Relationship; Tropanes

2011
New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
    Journal of medicinal chemistry, 2012, Feb-23, Volume: 55, Issue:4

    Topics: Animals; Antipsychotic Agents; Brain; CHO Cells; Cricetinae; Cricetulus; Humans; In Vitro Techniques; Male; Models, Molecular; Organ Specificity; Oxazepines; Piperazines; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Receptors, Dopamine D4; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Structure-Activity Relationship

2012
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013
Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
    Bioorganic & medicinal chemistry, 2016, 09-15, Volume: 24, Issue:18

    Topics: Animals; Antipsychotic Agents; Benzene Derivatives; Dopamine D2 Receptor Antagonists; Male; Mice; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin 5-HT2 Receptor Antagonists; Stereoisomerism; Structure-Activity Relationship; Tropanes

2016
Identification of 2-fluoro-8-methyl-11-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine with clozapine-like mixed activities at muscarinic acetylcholine, dopamine, and serotonin receptors.
    Bioorganic & medicinal chemistry letters, 2021, 05-15, Volume: 40

    Topics: Acetylcholine; Animals; Antipsychotic Agents; Azepines; Cholinergic Agents; Clozapine; Dopamine; Drug Evaluation, Preclinical; Humans; Mice; Olanzapine; Protein Binding; Quetiapine Fumarate; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Serotonin; Small Molecule Libraries; Structure-Activity Relationship

2021